Marcus P Kelly

ORCID

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 3

Top Venues

Molecular cancer therapeutics

Cancer immunology research

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Richard Tavaré, Makenzie Danton, Jason T Giurleo, Sosina Makonnen, Carlos Hickey, Tomas C Arnold, Marcus P Kelly, Fanny Fredriksson, Karina Bruestle, Aynur Hermann, Erica Ullman, Kurt H Edelmann, Terra Potocky, Drew Dudgeon, Nikunj B Bhatt, Mikhail Doubrovin, Thomas Barry, Christos A Kyratsous, Cagan Gurer, Naxin Tu, Hans Gartner, Andrew J Murphy, Lynn E Macdonald, Jon Popke, Akiva Mintz, Adam Griesemer, William C Olson, Gavin Thurston, Dangshe Ma, Jessica R Kirshner
Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054. Cancer immunology research 10 (10) (2022)
Marcus P Kelly, Sosina Makonnen, Carlos Hickey, T Cody Arnold, Jason T Giurleo, Richard Tavaré, Makenzie Danton, Christian Granados, Ishita Chatterjee, Drew Dudgeon, Marc W Retter, Dangshe Ma, William C Olson, Gavin Thurston, Jessica R Kirshner
Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues. Journal for immunotherapy of cancer 9 (1) (2021)
John O DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C Franklin, Frank J Delfino, Shu Mao, Feng Zhao, Jason T Giurleo, Marcus P Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W Retter, Rabih Slim, Tara M Young, William C Olson, Gavin Thurston, Christopher Daly
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade. Molecular cancer therapeutics 20 (10) (2021)

Marcus P Kelly.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Marcus P Kelly